Clinical Trial Update: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating panobinostat, carfilzomib, and dexamethasone in relapsed or refractory multiple myeloma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)
• DEXAMETHASONE (Dexamethasone)
• Panobinostat (Panobinostat)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2022-05-09